These comprehensive results demonstrate that LK-A effectively inhibits tumor growth in vivo in mouse xenograft models of OSCC, with a concurrent decrease in p-Akt expression, highlighting its potential therapeutic efficacy against OSCC through the suppression of the PI3K/AKT pathway. The gene discussed is AKT1; the disease is neoplasm.